HK inno.N and Roche Korea collaborate to promote targeted anti마카오 카지노 바카라 drug 'Avastin'

[by Lee, Young Sung] HK inno.N announced on January 21 that it held an agreement ceremony with Roche Korea at Roche Korea headquarters the previous day (January 20) to jointly promote the targeted 마카오 카지노 바카라 drug ‘Avastin (bevacizumab)’.

As part of the agreement, HK inno.N will handle the marketing and sales of Avastin for colon 마카오 카지노 바카라 and gynecological 마카오 카지노 바카라. Roche Korea will concentrate on enhancing patient benefits through specialized research and clinical trials to improve the clinical value of Avastin, as well as exploring combination therapies with ‘Tecentriq (atezolizumab)’.

This partnership was established to meet the unmet medical needs of Korean patients and extend the clinical benefits of ‘Avastin’ to a larger patient population. HK 마카오 카지노 바카라.N anticipates that the agreement will strengthen its business model and organizational scale, with Roche’s deep expertise in Avastin and HK 마카오 카지노 바카라.N’s strong sales and marketing capabilities working together to create synergies.

“After our distribution and joint sales agreements for the influenza treatments Xofluza and Tamiflu with Roche Korea, I am honored to announce the joint promotion of Avastin this year,” expressed Kwak Dalwon, CEO of HK inno.N. “The prevalence of colon 마카오 카지노 바카라 and gynecological 마카오 카지노 바카라 is rapidly increasing due to aging and lifestyle changes, and we are committed to working with patients and their families to fight 마카오 카지노 바카라 through Avastin.”

“Innovation for patients remains Roche Korea’s top priority,” stated Ezat Azem, CEO of Roche Korea. “We hope that this agreement between the two companies will create synergies and positively impact the lives of more 마카오 카지노 바카라 patients.”

Avastin is the first angiogenesis inhibitor that pioneered the concept of ‘starving 마카오 카지노 바카라 to death.’ Since receiving FDA approval in 2004, it has been prescribed to over 4.2 million 마카오 카지노 바카라 patients worldwide over the past 20 years, providing treatment benefits to 340,000 patients annually. In Korea, it was initially approved in 2005 for metastatic colorectal 마카오 카지노 바카라 and has since been progressively expanded its indications to include a total of 7 마카오 카지노 바카라s, including non-small cell lung 마카오 카지노 바카라, renal cell carcinoma, epithelial ovarian 마카오 카지노 바카라, cervical 마카오 카지노 바카라, and glioblastoma. When combined with Tecentriq, it is now used to treat a total of 8 types of 마카오 카지노 바카라.